Skip to content
Hugin
An older man holding a closed folder sits in a mostly empty grey waiting room.

Hugin News

CMS finalizes Medicare drug negotiation regulations for prices beginning in 2029

2 min read

Original fictional editorial artwork from the Hugin archive; not documentary evidence or a depiction of any actual patient or institution.

This record was prepared on the date shown and recovered after a publishing interruption.

The Centers for Medicare & Medicaid Services has finalized regulations for Medicare's drug price negotiation program and Part D coverage. The rule takes legal effect December 5, 2026, but generally applies to negotiated prices in 2029 and later and to Part D coverage beginning January 1, 2029. Earlier negotiation years remain governed by existing guidance; this rule does not itself announce a newly negotiated drug price.

medicareprescription-drugsdrug-pricescmsfederal-rule
source receipt
1
source host
1
read time
2min
primary source
Linked

The Centers for Medicare & Medicaid Services finalized regulations for its prescription-drug price negotiation program Monday. Although the rule becomes legally effective December 5, 2026, its negotiation provisions generally govern prices beginning in 2029, not the prices already negotiated for earlier years.

What CMS put into regulations

The agency says the final rule largely codifies policies it had previously issued through program guidance. The negotiation program selects certain high-expenditure, single-source medicines covered under Medicare Part D or paid under Part B, negotiates a maximum fair price with manufacturers, and publishes that price. The new regulations set out the selection, negotiation, manufacturer-agreement and compliance processes in the Code of Federal Regulations.

CMS also finalized more specific policies. One addresses how to identify certain fixed-combination drugs that are new formulations when deciding what counts as a qualifying single-source drug. Others address how it reviews whether a generic or biosimilar is genuinely marketed, transfers a manufacturer's program responsibilities after an acquisition, and applies a temporary price floor for small biotechnology drugs in 2029 and 2030. These provisions affect how the agency and manufacturers administer future negotiation rounds; the rule does not by itself select a new medicine or state a new negotiated price.

The two clocks

The rule's December 5 effective date is separate from its applicability dates. CMS says its negotiation regulations apply beginning with initial price applicability year 2029. The agency expects drug selection and price negotiations for that year to occur during 2027. Its Part D coverage regulations apply beginning January 1, 2029.

CMS says the program guidance for the 2026, 2027 and 2028 initial price years remains in force for those years and is not superseded by this rule. That distinction matters to people comparing a drug's current negotiated price with a future program change: this final rule is a framework for later rounds, not a reset of the earlier ones. It gives no individual beneficiary's out-of-pocket amount.

Source links